Folfirinox gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study.

Fiche publication


Date publication

janvier 2019

Journal

Therapeutic advances in gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Mme POZET Astrid


Tous les auteurs :
Williet N, Saint A, Pointet AL, Tougeron D, Pernot S, Pozet A, Bechade D, Trouilloud I, Lourenco N, Hautefeuille V, Locher C, Desrame J, Artru P, Thirot Bidault A, Le Roy B, Pezet D, Phelip JM, Taieb J

Résumé

Folfirinox (FFX) and gemcitabine/nab-paclitaxel (GN) are both standard first-line treatments in patients with metastatic pancreatic cancer (mPC). However, data comparing these two chemotherapeutic regimens and their sequential use remain scarce.

Mots clés

Folfirinox, gemcitabine/nab-paclitaxel, metastatic, pancreatic adenocarcinoma, survival

Référence

Therap Adv Gastroenterol. 2019 ;12:1756284819878660